INT311478

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 5
Disease Relevance 2.38
Pain Relevance 2.34

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (Mllt1) nucleus (Mllt1) cytoplasm (Mllt1)
Mllt1 (Mus musculus)
Pain Link Frequency Relevance Heat
Lamotrigine 409 100.00 Very High Very High Very High
carbamazepine 40 98.28 Very High Very High Very High
antiepileptic Drug 74 90.68 High High
Gabapentin 9 47.44 Quite Low
headache 13 36.68 Quite Low
anticonvulsant 15 5.00 Very Low Very Low Very Low
Glutamate 5 5.00 Very Low Very Low Very Low
Bioavailability 4 5.00 Very Low Very Low Very Low
sodium channel 3 5.00 Very Low Very Low Very Low
cocaine 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Convulsion 197 99.96 Very High Very High Very High
Partial Seizures 32 99.04 Very High Very High Very High
Syndrome 33 80.28 Quite High
Epilepsy 48 52.24 Quite High
Generalized Epilepsy 53 41.28 Quite Low
Rhinitis 5 38.68 Quite Low
Ataxia 11 37.00 Quite Low
Headache 13 36.68 Quite Low
Diplopia 11 36.08 Quite Low
Vomiting 25 35.52 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For instance, carbamazepine (CBZ) and phenytoin (PHT) are strong inducers of UGT1A4 and their combined treatment with LTG results in a substantial increase in its systemic clearance.12,13 Also, enzyme inducers (ie, CBZ, PHT) are responsible for the significant reduction in the LTG’s elimination half-life from approximately 24 to 13 h.12,13 In contrast, valproate (VPA) as an inhibitor of glucuronidation has been documented to significantly reduce the clearance of LTG with a concomitant increase in its elimination half-life from approximately 37 to 48 h.14 Moreover, LTG serum concentrations were significantly increased from 4.67 ± 3.66 (LTG monotherapy) to 9.56 ± 5.27 ?
Positive_regulation (increased) of LTG associated with lamotrigine and carbamazepine
1) Confidence 0.60 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 0 Pain Relevance 0.71
For instance, carbamazepine (CBZ) and phenytoin (PHT) are strong inducers of UGT1A4 and their combined treatment with LTG results in a substantial increase in its systemic clearance.12,13 Also, enzyme inducers (ie, CBZ, PHT) are responsible for the significant reduction in the LTG’s elimination half-life from approximately 24 to 13 h.12,13 In contrast, valproate (VPA) as an inhibitor of glucuronidation has been documented to significantly reduce the clearance of LTG with a concomitant increase in its elimination half-life from approximately 37 to 48 h.14 Moreover, LTG serum concentrations were significantly increased from 4.67 ± 3.66 (LTG monotherapy) to 9.56 ± 5.27 ?
Positive_regulation (results) of LTG associated with lamotrigine and carbamazepine
2) Confidence 0.43 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 0.37 Pain Relevance 0.72
Although both LTG-IR and LTG-XR are approved for use as adjunctive treatment of partial seizures and primary generalized tonic-clonic seizures, LTG-IR has been approved for a wider age range, starting with patients at the age of two years, whereas LTG-XR is only approved for those over 13 years of age.
Positive_regulation (approved) of LTG-XR associated with convulsion and partial seizures
3) Confidence 0.41 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998806 Disease Relevance 0.95 Pain Relevance 0.12
For instance, carbamazepine (CBZ) and phenytoin (PHT) are strong inducers of UGT1A4 and their combined treatment with LTG results in a substantial increase in its systemic clearance.12,13 Also, enzyme inducers (ie, CBZ, PHT) are responsible for the significant reduction in the LTG’s elimination half-life from approximately 24 to 13 h.12,13 In contrast, valproate (VPA) as an inhibitor of glucuronidation has been documented to significantly reduce the clearance of LTG with a concomitant increase in its elimination half-life from approximately 37 to 48 h.14 Moreover, LTG serum concentrations were significantly increased from 4.67 ± 3.66 (LTG monotherapy) to 9.56 ± 5.27 ?
Positive_regulation (increase) of LTG associated with lamotrigine and carbamazepine
4) Confidence 0.40 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 0.16 Pain Relevance 0.70
Although both LTG-IR and LTG-XR are approved for use as adjunctive treatment of partial seizures and primary generalized tonic-clonic seizures, LTG-IR has been approved for a wider age range, starting with patients at the age of two years, whereas LTG-XR is only approved for those over 13 years of age.
Positive_regulation (approved) of LTG-IR associated with convulsion and partial seizures
5) Confidence 0.36 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998806 Disease Relevance 0.91 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox